Novartis receives positive CHMP opinion to expand Kisqali® combination therapy
Novartis announced the CHMP of the EMA has adopted a positive opinion recommending an expanded indication for Kisqali® (ribociclib), the CDK4/6 inhibitor with the largest body of first-line clinical trial evidence demonstrating consistent, superior and sustained efficacy versus endocrine therapy. November 16, 2018